Press release
Gossamer Bio Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
– Clinical trial results for all four clinical-stage product candidates in target areas of immunology, inflammation and oncology expected in 2020 – – Cash,
About this update from Gossamer Bio, Inc.
[{"type":"text","content":"\n– Clinical trial results for all four clinical-stage product candidates in target areas of immunology, inflammation and oncology expected in 2020 –\n\n\n– Cash, cash equivalents and marketable securities totaled $401.8 million at year-end 2019 –\n\n SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the fourth quarter and year ended December 31, 2019 and provided a business update.\n\n\n“Our hearts are with the patients, families, caregivers and medical professionals suffering and sacrificing in the ongoing Covid-19 viral pandemic. We are monitoring the situation on a daily basis to understand the impact on Gossamer and our programs and are taking the necessary actions now to do what is best for our patients, employees and company,” said Sheila Gujrathi, M.D., Co-Founder and Chief Executive Officer of Gossamer Bio.\n\n\n“2019 was a year of execution for Gossamer Bio, as we continued to advance all four of our clinical-stage product candidates in our target areas of immunology, inflammation and oncology. Notwithstanding the Covid-19 pandemic, we expect to continue our momentum in 2020, with data from all of our candidates expected this year. We are committed to advancing our product candidates and the field of medicine for the betterment of patients and their families, and we look forward to providing updates on these efforts throughout the year.”\n\n\nClinical-Stage Product Candidate Updates\n\n\nGB001: Oral DP2 Antagonist for Eosinophilic Asthma and Chronic Rhinosinusitis (CRS)\n\n\n\nGossamer has made available three poster presentations from its GB001 program for patients with asthma. All three posters, which Gossamer had planned to present at the now cancelled 2020 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, can be found in the Posters and Publications section of Gossamer’s website:\n\n\n“Effect of the DP2 Antagonist GB001 on Asthma Worsening in Patients with Mild-Moderate Asthma” showed that GB001 treatment is associated with longer time to asthma worsening / exacerbation and observed treatment effects were greater in the populations with higher baseline FeN...